Although the clinical application and therapeutic effects of directly administered recombinant IFN-γ in cancer patients appears marginal, there is limited experience in investigations focused on therapies utilizing direct transfer of tumor-reactive CD4 T cells secreting IFN-γ. This evidence concerns the gene CD4 and cancer.